Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Lyrfigtu (Lirafugratinib) Medicine in India

Lyrfigtu (Lirafugratinib)

Medicine name : Lyrfigtu

Generic name : Lirafugratinib

Manufactured By : Elevar Therapeutics, Inc.

Indications : Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

Medicine Description : A targeted therapy for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. Lyrfigtu (Lirafugratinib) is an oral kinase inhibitor that selectively targets FGFR2, a protein involved in cancer cell growth and survival. By blocking abnormal FGFR2 signaling, it helps inhibit the growth and proliferation of cancer cells. It is used for eligible adult patients whose cancer has progressed following previous systemic treatment.

Product Introduction

Lyrfigtu (Lirafugratinib) is a targeted anticancer medicine used to treat adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. It belongs to a group of medicines called kinase inhibitors and works by selectively blocking FGFR2 activity, which plays an important role in cancer-cell growth and survival. By inhibiting this pathway, Lyrfigtu helps slow tumor growth and disease progression.

Lyrfigtu (Lirafugratinib) is taken orally once daily, with or without food, as prescribed by your doctor. The recommended starting dose is 70 mg daily, and the capsules should be swallowed whole without opening, breaking, or chewing them. Treatment generally continues until the cancer progresses or side effects become unacceptable. Regular eye examinations and blood tests are important to monitor treatment response and identify possible complications.

Common side effects of Lyrfigtu (Lirafugratinib) may include nail problems, hand-foot skin reactions, mouth inflammation, hair loss, dry eyes, dry mouth, fatigue, changes in taste, constipation, dry skin, rash, abdominal pain, diarrhea, nausea, and decreased appetite. Serious complications may include retinal toxicity and vision changes, high phosphate levels, soft tissue or blood vessel calcification, bleeding, and embryo-fetal harm. Inform your doctor about all medicines and supplements you take, and report blurred vision, eye discomfort, unusual bleeding, or severe skin reactions promptly. Women who can become pregnant should use effective contraception during treatment and for 6 months after the last dose.

Uses Of Lyrfigtu (Lirafugratinib)

Treatment of FGFR2-Positive Cholangiocarcinoma (Bile Duct Cancer)

Benefits Of Lyrfigtu

Lyrfigtu (Lirafugratinib) is used to treat adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma containing FGFR2 gene fusions or rearrangements. It works by selectively blocking FGFR2 proteins involved in cancer-cell growth and survival, helping slow tumor progression and manage the disease.

Side Effects Of Lyrfigtu (Lirafugratinib)

Some side effects of Lyrfigtu (Lirafugratinib) may improve as your body adjusts to the treatment. Consult your doctor if they persist, become severe, or cause concern.

Common Side Effects of Lyrfigtu (Lirafugratinib)

  • Nail problems
  • Hand-foot skin reaction
  • Mouth sores or inflammation
  • Hair loss
  • Dry eyes
  • Dry mouth
  • Fatigue
  • Changes in taste
  • Constipation
  • Dry skin
How To Use Lyrfigtu

Lyrfigtu (Lirafugratinib) should be taken orally once daily, with or without food, exactly as prescribed by your doctor. The recommended starting dose is 70 mg daily. Swallow the capsules whole with water without opening, breaking, or chewing them. Treatment generally continues until the cancer progresses or side effects become unacceptable. Regular eye examinations, blood phosphate measurements, and other medical check-ups are required to monitor for complications.

How Lyrfigtu (Lirafugratinib) Works

Lyrfigtu is a selective fibroblast growth factor receptor 2 (FGFR2) kinase inhibitor. It works by blocking abnormal FGFR2 signalling caused by gene fusions or rearrangements in cancer cells. This pathway plays an important role in tumor growth, multiplication, and survival. By inhibiting FGFR2 activity, Lyrfigtu helps reduce cancer-cell growth and slow the progression of cholangiocarcinoma.

Storage Conditions
  • Store at room temperature between 20°C and 25°C.
  • Temporary temperature excursions between 15°C and 30°C are permitted.
  • Keep the capsules in their original child-resistant DosePak blister packaging until use..
  • Store in a dry place, away from excessive heat and moisture, and keep out of reach of children.
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Avoid excessive alcohol consumption during treatment with Lyrfigtu (Lirafugratinib), as alcohol may add to the strain on the liver. Consult your doctor before consuming alcohol.

PregnancyPregnancy CONSULT YOUR DOCTOR

Lyrfigtu may cause harm to an unborn baby. It is not recommended during pregnancy. Women who can become pregnant should use effective contraception during treatment and for 6 months after the last dose.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment with Lyrfigtu (Lirafugratinib) and for 1 week after the last dose. Consult your doctor for guidance.

DrivingDriving CONSULT YOUR DOCTOR

Lyrfigtu may cause fatigue, dizziness, or vision changes that can affect concentration and alertness. Avoid driving or operating machinery if you experience these effects.

KidneyKidney CAUTION

Inform your doctor if you have kidney problems before starting Lyrfigtu. Your doctor may monitor kidney function and blood phosphate levels during treatment, as increased phosphate levels can lead to mineral deposits in body tissues.

LiverLiver CAUTION

Inform your doctor if you have liver disease before starting Lyrfigtu. Liver enzyme changes may occur during treatment, and your doctor may recommend regular blood tests to monitor liver function.

Quick Tips
  • Take Lyrfigtu once daily exactly as prescribed by your doctor.
  • Swallow the capsules whole with water; do not open, crush, or chew them.
  • Attend regular eye examinations to monitor possible vision-related complications.
  • Follow scheduled blood tests to monitor phosphate levels and other health parameters.
  • Report vision changes, severe skin reactions, unusual bleeding, or persistent fever to your doctor promptly.
  • Read More About - Lyrfigtu (Lirafugratinib) from Pharma Five.
About Pharma Five

Pharma Five assists patients who need Lyrfigtu (Lirafugratinib) by supporting the import of limited quantities for personal medical treatment, subject to applicable regulations. Depending on the requirements, the process may involve Form 12A, a valid prescription from a Registered Medical Practitioner (RMP), and other supporting documents.

With over 20 years of experience in the pharmaceutical industry, Pharma Five provides consultancy and medicine import assistance for patients seeking access to Lyrfigtu (Lirafugratinib). The team offers guidance on necessary documentation and helps patients understand the relevant import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB18300
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220425Orig1s000lbl.pdf
  3. https://pubchem.ncbi.nlm.nih.gov/compound/155309155
Faq

General Question

Lyrfigtu (Lirafugratinib) is a targeted anticancer medicine used to treat adults with previously treated, unresectable or metastatic cholangiocarcinoma containing FGFR2 gene fusions or rearrangements.

Lyrfigtu works by selectively blocking FGFR2 proteins that contribute to cancer-cell growth and survival, helping slow the progression of bile duct cancer.

Lyrfigtu is prescribed for adults with previously treated, unresectable, locally advanced or metastatic FGFR2-positive cholangiocarcinoma.

Take Lyrfigtu orally once daily as prescribed. Swallow the capsules whole without opening, crushing or chewing them.

Common side effects include nail problems, hand-foot skin reactions, mouth sores, hair loss, dry eyes, dry mouth, fatigue, taste changes, constipation and dry skin.

Yes. Serious side effects may include retinal problems, vision changes, high phosphate levels, tissue calcification and bleeding. Contact your doctor if concerning symptoms occur.

Continue taking Lyrfigtu until your cancer progresses or side effects become unacceptable, as determined by your treating doctor.

Consult your doctor before drinking alcohol during treatment. Avoid excessive alcohol consumption.

Lyrfigtu may harm an unborn baby. Effective contraception is recommended during treatment and for 6 months after the last dose for women who can become pregnant.

Lyrfigtu may interact with certain medicines, including CYP3A inducers and medicines affected by drug transporters. Inform your doctor about all medicines and supplements you take.

If you miss a dose, take it within 4 hours of the scheduled time. If more than 4 hours have passed, skip the missed dose and take the next dose at the usual time. Do not take an extra dose.

Yes. Lyrfigtu can be taken with or without food. Take it consistently as directed by your doctor.

Attend regular eye examinations and blood tests, especially phosphate monitoring. Inform your doctor about other medicines and report vision changes or unusual bleeding promptly.

Store Lyrfigtu at 20°C to 25°C, with permitted excursions between 15°C and 30°C. Keep it in its original packaging and protect it from moisture.

Pharma Five may assist patients seeking Lyrfigtu through medicine import support, subject to applicable regulations and required medical documentation. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources